The insider selling is routine and non-informative given the small size relative to market cap and the simultaneous equity grants. Monitor for any upcoming catalyst (e.g., clinical data readout) that could explain the timing, but this cluster alone does not warrant a bearish stance.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $10.42entry
- T+1 · 2mo ago −1.92%α −2.77% · $10.22
- T+5 · 2mo ago −19.00%α −19.63% · $8.44
- T+20 · 6w ago −34.74%α −37.12% · $6.80
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider selling at Artiva Biotherapeutics, totaling $477K, was driven by the CEO, COO, CTO, and CMO. The CEO's $256K sale is the largest, but the total represents only ~0.09% of the $509M market cap, falling below the 0.1% materiality threshold. This is a routine, low-significance event, especially given the simultaneous large equity grants to the same executives, which are non-cash and likely set up a 10b5-1 plan for tax or diversification purposes.
Key Financial Metrics
Key Facts
- Total insider selling of $477K represents ~0.09% of ARTV's $509M market cap, below the 0.1% materiality threshold.
- CEO Fred Aslan sold 23,429 shares for $256K on 2026-09-08, the largest single trade in the cluster.
- COO Jennifer Bush, CTO Christopher Horan, and CMO Subhashis Banerjee also sold shares totaling $222K on 2026-09-03.
- All four selling insiders received large equity grants on 2026-09-09 (non-cash, $0 value), suggesting the sales may be liquidity-driven to cover taxes or diversify after vesting.
- No open-market buying was reported in the cluster, and all sales are open-market (code S).
Financial Impact
Total insider sales of $477K, or ~0.09% of market cap. No material financial impact.
Risk Factors
- Insider selling could accelerate if the stock price rises further, creating overhead supply.
- The company is a pre-revenue biotech with no approved products, so any clinical or regulatory setback could be severe.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ARTV-1789168934207 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Viewing Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers